Edition:
United States

Array Biopharma Inc (ARRY.OQ)

ARRY.OQ on NASDAQ Stock Exchange Global Market

19.55USD
21 Jun 2018
Change (% chg)

-- (--)
Prev Close
$19.55
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
754,553
52-wk High
$20.20
52-wk Low
$7.15

Select another date:

Wed, May 9 2018

BRIEF-Array Biopharma Says Entered Into Controlled Equity Offerings Sales Agreement With Cantor Fitzgerald

* ARRAY BIOPHARMA INC SAYS ENTERED INTO CONTROLLED EQUITY OFFERINGSM SALES AGREEMENT WITH CANTOR FITZGERALD & CO - SEC FILING

BRIEF-Array Biopharma Reports Q3 Loss Per Share $0.11

* ARRAY BIOPHARMA REPORTS FINANCIAL RESULTS FOR THE THIRD QUARTER OF FISCAL 2018

Array melanoma drugs show significant survival versus Roche drug in study

A combination of experimental drugs from Array BioPharma Inc kept patients with advanced melanoma associated with a common gene mutation alive for nearly three years and twice as long as a rival Roche Holding AG medicine, according to data from a late stage study released on Tuesday.

UPDATE 1-Array melanoma drugs show significant survival vs Roche drug in study

Feb 6 A combination of experimental drugs from Array BioPharma Inc kept patients with advanced melanoma associated with a common gene mutation alive for nearly three years and twice as long as a rival Roche Holding AG medicine, according to data from a late stage study released on Tuesday.

BRIEF-Array Biopharma Q2 Loss Per Share $0.17

* ARRAY BIOPHARMA REPORTS FINANCIAL RESULTS FOR THE SECOND QUARTER OF FISCAL 2018

Array melanoma drugs show significant survival vs Roche drug in study

Feb 6 A combination of experimental drugs from Array BioPharma Inc kept patients with advanced melanoma associated with a common gene mutation alive for nearly three years and twice as long as a rival Roche Holding AG medicine, according to data from a late stage study released on Tuesday.

AstraZeneca is sued by Array BioPharma over cancer drug royalties

NEW YORK Array BioPharma Inc on Thursday sued AstraZeneca AB, accusing the pharmaceutical company of refusing to pay required royalties for a cancer drug after entering into an $8.5 billion collaboration with Merck & Co.

AstraZeneca is sued by Array BioPharma over cancer drug royalties

NEW YORK, Feb 1 Array BioPharma Inc on Thursday sued AstraZeneca AB, accusing the pharmaceutical company of refusing to pay required royalties for a cancer drug after entering into an $8.5 billion collaboration with Merck & Co.

BRIEF-Array Biopharma Says Its partner Seeks Withdrawal of Marketing Authorization Applications For Binimetinib Monotherapy in EU, Switzerland And Australia

* ARRAY BIOPHARMA SAYS PIERRE FABRE MEDICAMENT, REQUESTED THAT MARKETING AUTHORIZATION APPLICATIONS FOR BINIMETINIB MONOTHERAPY BE WITHDRAWN

BRIEF-Aslan Pharmaceuticals buys full global commercial rights for Varlitinib

* ASLAN PHARMACEUTICALS ACQUIRES FULL GLOBAL COMMERCIAL RIGHTS FOR VARLITINIB FROM ARRAY BIOPHARMA

Select another date: